Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2010; 5(9): e12925.
Published online 2010 September 23. doi:  10.1371/journal.pone.0012925
PMCID: PMC2944871

1,25-Dihydroxyvitamin D3 Inhibits the Differentiation and Migration of TH17 Cells to Protect against Experimental Autoimmune Encephalomyelitis

Derya Unutmaz, Editor



Vitamin D3, the most physiologically relevant form of vitamin D, is an essential organic compound that has been shown to have a crucial effect on the immune responses. Vitamin D3 ameliorates the onset of the experimental autoimmune encephalomyelitis (EAE); however, the direct effect of vitamin D3 on T cells is largely unknown.

Methodology/Principal Findings

In an in vitro system using cells from mice, the active form of vitamin D3 (1,25-dihydroxyvitamin D3) suppresses both interleukin (IL)-17-producing T cells (TH17) and regulatory T cells (Treg) differentiation via a vitamin D receptor signal. The ability of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) to reduce the amount of IL-2 regulates the generation of Treg cells, but not TH17 cells. Under TH17-polarizing conditions, 1,25(OH)2D3 helps to increase the numbers of IL-10-producing T cells, but 1,25(OH)2D3's negative regulation of TH17 development is still defined in the IL-10−/− T cells. Although the STAT1 signal reciprocally affects the secretion of IL-10 and IL-17, 1,25(OH)2D3 inhibits IL-17 production in STAT1−/− T cells. Most interestingly, 1,25(OH)2D3 negatively regulates CCR6 expression which might be essential for TH17 cells to enter the central nervous system and initiate EAE.


Our present results in an experimental murine model suggest that 1,25(OH)2D3 can directly regulate T cell differentiation and could be applied in preventive and therapeutic strategies for TH17-mediated autoimmune diseases.


Interleukin (IL)-17-producing T cells have been identified in the mouse as a new lineage of CD4+ T cells that can be differentiated from naïve T cells by the polarizing cytokines TGF-β, IL-6, and IL-23 [1][4]. TH17 cells can protect against bacterial pathogens by recruiting neutrophils but have also been reported to develop into an immunopathology in various models of autoimmunity [1][4].

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by inflammatory cell infiltration and subsequent demyelination of axonal tracts in the brain and spinal cord [5]. Demyelination disturbs the conduction of neuronal signals along axons, resulting in clinical symptoms including pain, fatigue, muscle weakness, and visual disturbances [5]. Several studies report that TH17 cells are involved in the initiation and maintenance of experimental autoimmune encephalomyelitis (EAE), a murine model of MS [6], [7]. In addition, recent studies suggest that TH17 cells (i.e., IL-17+ TH17 cells) have a high inflammatory potential and may constitute a relevant inflammatory subset in human MS [8], [9]. Some of these TH17 cells secrete IFN-γ (i.e., IFN-γ+ TH17 cells), which preferentially migrates into the CNS in human MS [10], [11].

Although the exact cause of MS remains unclear, genetic background and/or unknown environmental factors are believed to contribute to the onset of the disease. Epidemiological studies have shown that geographical location is associated with the incidence of MS, which increases with latitude in both hemispheres [12]. One potential explanation is that susceptibility to MS is related to exposure to sunlight and the subsequent production of vitamin D [13]. In one recent study, levels of vitamin D were significantly lower in relapsing-remitting patients than in healthy controls [14]. In addition, the level of vitamin D production in MS patients suffering a relapse was lower than in patients during remission [14]. Furthermore, vitamin D supplementation and higher levels of vitamin D in circulation are associated with a decreased incidence of MS [15], [16].

Vitamin D is a well-known nutrient that acts as a modulator of calcium homeostasis and the immune response [17], and the vitamin D receptor (VDR) is expressed in several types of immune cells, including monocytes, macrophages, dendritic cells (DCs), and effector/memory T cells [18][20]. In in vitro studies, 1,25(OH)2D3 inhibits T cell proliferation, the production of IL-2 and IFN-γ and cytotoxicity [21][23]. 1,25(OH)2D3 negatively regulates the differentiation, maturation, and immunostimulatory capacity of DCs by decreasing the expression of MHC class II, CD40, CD80, and CD86 [24][26]. In addition, 1,25(OH)2D3 decreases the synthesis of IL-6, IL-12, and IL-23 [27][29]. Hence it seems likely that 1,25(OH)2D3 suppresses the generation of TH1 and TH17 cells and probably induces the development of forkhead box protein 3 (Foxp3)+ Treg cells. However, the direct effect of 1,25(OH)2D3 on the function and differentiation of T cells is largely unknown because VDR is not expressed in naïve T cells [30]. Thus, these inhibitory effects of 1,25(OH)2D3 are most pronounced in the effector/memory T cells which do express VDR or are mediated by 1,25(OH)2D3-treated DCs.

In this study, we addressed whether 1,25(OH)2D3 directly down-regulates the development of both Treg and TH17 cells. These inhibitory capabilities of 1,25(OH)2D3 are dependent on the VDR signal in activated CD4+ T cells. Importantly, 1,25(OH)2D3 regulates the migration of TH17 cells into the CNS by suppressing CCR6 expression. Our findings establish that oral treatment with systemic 1,25(OH)2D3 directly modulates to T cells to prevent both the development of TH17 cells and the expression of CCR6 in EAE-induced conditions. Therefore, vitamin D3 could be applicable in both preventive and therapeutic strategies for TH17-mediated autoimmune disease.


1,25(OH)2D3 inhibits the onset of EAE and alters TH cell composition

To develop an animal experimental model of EAE, B6 mice were immunized subcutaneously with a peptide consisting of myelin oligodendrocyte glycoprotein (MOG33–55) in complete Freund's adjuvant (CFA) and pertussis toxin as described elsewhere [31][34]. The severity of the resulting paralysis was determined as a disease score. Symptoms were shown at 9 days after challenge and high severity of paralysis was shown at about 20 days (Figure 1A). To confirm whether vitamin D3 inhibits EAE initiation, mice were orally treated with 1,25(OH)2D3 as described elsewhere [32]. Of note, most 1,25(OH)2D3-treated mice were completely resistant to the development of EAE (Figure 1A). Since previous studies demonstrated that autoreactive T cells, especially TH1 and TH17, are essential to induce EAE, we further analyzed TH cells in EAE-induced mice. To this end, mononuclear cells in the CNS (including the brain and spinal cord) were enriched by density gradient and analyzed by flow cytometry. As depicted in Figure 1B, significantly fewer infiltrated CD4+ T cells were present in the CNS of the 1,25(OH)2D3-treated EAE-induced mice than in the CNS of PBS-treated EAE-induced mice. We further analyzed the TH differentiation in the spleen and CNS of EAE-induced mice with and without oral 1,25(OH)2D3. As expected, IL-17-secreting TH17 cells were predominant in the spleen of EAE-induced mice when compared with the untreated wild-type B6 mice (Figure 1C). Of note, oral treatment with 1,25(OH)2D3 dramatically reduced the numbers of TH17 cells in the spleen of EAE-induced mice (Figure 1C, p = 0.00114). In addition, increased numbers of TH17 cells were detected in the CNS of EAE-induced mice (Figure 1C) whereas no TH17 cells were detected in the CNS of 1,25(OH)2D3-treated mice (data not shown). The number of Foxp3+ cells in the spleen of 1,25(OH)2D3-treated mice was slightly decreased, but the numbers of IL-10 and IFN-γ expressing cells in the spleen of all groups of mice were identical. Taken together, these results suggest that vitamin D3 may regulate the differentiation and/or migration of CD4+ T cells in the EAE inductive phase.

Figure 1
1,25(OH)2D3 inhibits the onset of EAE and modulates the composition of TH cells.

1,25(OH)2D3 inhibits in vitro differentiation of both Treg and TH17 cells

We next examined the potential role of vitamin D3 on TH generation by using well-established in vitro conditions. An in vitro treatment of 1,25(OH)2D3 on MOG-specific CD4+ T cells in the presence of MOG peptide, antigen-presenting cells (APCs), and TGF-β inhibited the expression of Foxp3 (Figure 2). Of note, 1,25(OH)2D3 also inhibited the generation of IL-17-secreting cells in the presence of TGF-β and IL-6 (Figure 2). In addition, since an inhibitory role of vitamin D3 on TH1 differentiation has been reported [35], we investigated the effect of 1,25(OH)2D3 under TH1 polarizing-conditions. However, the effect of 1,25(OH)2D3 on the differentiation of IFN-γ-secreting cells was not addressed in our system (Figure 2). To make clear whether 1,25(OH)2D3 can directly inhibit TH17 T cell differentiation regardless of antigen type, we used DO11.10 mice, which have OVA-specific CD4+ T cells. An in vitro culture of naïve KJ1-26+CD4+ T cells with 1,25(OH)2D3 in the presence of OVA peptide and APCs significantly inhibited the generation of both Foxp3 and IL-17-secreting cells (Figure 3A). Similar to MOG-specific CD4+ T cells, 1,25(OH)2D3 did not affect the differentiation of IFN-γ-secreting cells (Figure 3A). The mRNA levels of Foxp3 and IL-17 also declined in 1,25(OH)2D3-treated CD4+ T cells (Figure 3B). We also confirmed that 1,25(OH)2D3 inhibited Foxp3 and IL-17 expression in a dose-dependent manner (data not shown). Overall, our results demonstrate that vitamin D3 has a significant suppressive effect on Treg and TH17 generation but not on TH1 differentiation.

Figure 2
1,25(OH)2D3 negatively regulates Treg and TH17 induction in neuro-antigen-specific CD4+ T cells.
Figure 3
1,25(OH)2D3 negatively regulates Treg and TH17 induction in OVA-specific CD4+ T cells.

Inhibition of Treg and TH17 differentiation by 1,25(OH)2D3 is dependent on the VDR on CD4+ T cells

The biological actions of vitamin D3 are mediated through the VDR, a member of the nuclear receptor superfamily [36]. To investigate whether VDR is essential for vitamin D3 to regulate TH cell differentiation, we used VDR−/− mice. As expected, deficiency of the VDR did not influence Treg and TH17 differentiation (Figure 4A and B). Of note, CD4+ T cells isolated from VDR−/− mice were resistant to the inhibitory effect of vitamin D3 on the differentiation of Treg (Figure 4A) and TH17 (Figure 4B) under polarizing conditions. In contrast, the inhibitory role of 1,25(OH)2D3 on Treg and TH17 differentiation was still shown when VDR−/− APCs were adopted (Figure 4A and B). Therefore, the VDR signal on activated CD4+ T cells was essential to down-regulate the development of Treg and TH17 cells.

Figure 4
Vitamin D receptor on CD4+ T cells is required for regulation of Treg and TH17 differentiation by 1,25(OH)2D3.

Down-regulation of Treg differentiation by 1,25(OH)2D3 is dependent on the low production of IL-2

Since vitamin D3 inhibits the secretion of IL-2, which is essential for the generation of Treg cells [37], [38], we first measured IL-2 levels in the culture supernatant after stimulation with vitamin D3. Interestingly, co-culture with vitamin D3 decreased IL-2 production by CD4+ T cells in a dose-dependent manner (Figure 5A). To investigate whether IL-2 recovers from the decrease of Treg differentiation caused by 1,25(OH)2D3, we added recombinant IL-2 (rIL-2) on the culture medium of CD4+ T cells in the presence of TGF-β and 1,25(OH)2D3. The addition of rIL-2 resulted in recovery of the Foxp3+ Treg cells that had been decreased by vitamin D3 compared with the numbers of Treg cells in the TGF-β-alone group (Figure 5B). However, in contrast to recovery of Treg cells following the addition of rIL-2, addition of rIL-2 did not reverse the inhibitory role of vitamin D3 on the generation of TH17 cells (Figure 5C). These results suggest that vitamin D3's ability to decrease the number of Treg cells may be the result of its inhibitory effect on the amount of IL-2 secreted by CD4+ T cells.

Figure 5
Exogenous IL-2 recovers the decreased Treg but not TH17 generation by 1,25(OH)2D3.

Regulation of TH17 differentiation by vitamin D3 is independent of IL-10

Since a previous study showed that IL-10 plays a crucial role in the vitamin D3-mediated inhibition of EAE [32], we further assessed the role of IL-10 on the inhibition of IL-17 production by 1,25(OH)2D3 in activated T cells upon stimulation with TGF-β and IL-6. Treatment with 1,25(OH)2D3 alone did not increase the number of IL-10-producing T cells whereas co-treatment with TGF-β and 1,25(OH)2D3 led to a brisk increase in the number of IL-10-producing CD4+ T cells (Figure 6A and B), and co-treatment with IL-6 synergistically helped to produce IL-10 (Figure 6C). We then explored the dose-dependency of 1,25(OH)2D3 on IL-10 secretion under TH17-polarizing conditions. Treatment of CD4+ T cells with 1,25(OH)2D3 in the presence of TGF-β and IL-6 enhanced IL-10 production in a dose-dependent manner (Figure 6D).

Figure 6
1,25(OH)2D3 and TGF-β plus IL-6 partially induce IL-10 production, but IL-10 is not involved in the inhibitory mechanism of vitamin D3.

Previous studies reported that IL-27 was up-regulated in APCs isolated from the CNS and lymph nodes of EAE-induced mice [39]. In addition, a combination of IL-27 and TGF-β has been shown to promote the differentiation of IL-10-producing Tr-1 cells [34], [40]. Therefore, it is possible that vitamin D3 might cooperate with IL-27 to suppress TH17 differentiation through IL-10. Interestingly, under TH17-polarizing conditions, treatment with a combination of IL-27 and 1,25(OH)2D3 generated a significantly higher number of IL-10-secreting cells when compared with the number of IL-10-secreting cells produced following treatment with IL-27 alone (Figure 6E). These data suggest that enhanced IL-10 production following treatment with vitamin D3 may regulate TH17 differentiation via an autocrine effect in the EAE inductive phase. To clarify the exact role of IL-10 in the suppression of TH17 differentiation by vitamin D3, we adopted IL-10−/− mice. Under TH17-polarizing conditions, treatment with 1,25(OH)2D3 decreased IL-17 expression in T cells isolated from both IL-10+/+ and IL-10−/− mice (Figure 6F). These results imply that IL-10 might not be directly involved in the suppressive role that vitamin D3 has on TH17 differentiation. Moreover, vitamin D3 may be a “helper” in the generation of IL-10-producing cells in an inflammatory environment but the effect of IL-10 is not essential for vitamin D3's negative regulation of TH17 generation.

The mechanism of suppression of TH17 generation by 1,25(OH)2D3 is independent on STAT1

Since the effect of vitamin D3 is similar to that of IL-27, which inhibits the development of TH17 cells through STAT1-dependent mechanisms [41][43], we adopted STAT1−/− mice to help us address the role that STAT1 signaling has on vitamin D3's inhibitory effect on TH17 differentiation. As expected, IL-27 failed to inhibit TH17 development in STAT1−/− T cells under TH17-polarizing conditions (Figure 7). However, under TH17-polarizing conditions, 1,25(OH)2D3 suppressed IL-17 expression in both STAT1−/− and STAT1+/+ CD4+ T cells (Figure 7). These results indicate that the negative regulation of TH17 by vitamin D3 is independent on STAT1.

Figure 7
The inhibitory mechanism of 1,25(OH)2D3 is independent of the STAT1 signal.

1,25(OH)2D3 negatively regulates the expression and migration of CCR6+ T cells

A recent study reported that the CCR6-CCL20 axis plays an essential role in controlling the entry of TH17 cells into the CNS and thus mediates the initiation of EAE [44]. In our present study, we found significantly reduced migration of CD4+ T cells into the CNS following oral feeding of 1,25(OH)2D3 (Figure 1B). To investigate the direct effect of vitamin D3 on the migration of TH17 cells into the CNS, we analyzed the CCR6 expression of the OVA-specific CD4+ T cells under TH17-polarizing conditions. Interestingly, 1,25(OH)2D3 directly inhibited CCR6 expression in the presence of TGF-β and IL-6 (Figure 8A). We further checked the expression levels of CCR6 in an EAE-relevant T cell system. Interestingly, 1,25(OH)2D3 reduced the expression of CCR6 on activated MOG-specific CD4+ T cells (data not shown). To further address the regulation of CCR6 expression by 1,25(OH)2D3, we evaluated the migratory characteristics of TH17 cells generated in vitro using the Transwell chemotaxis assay. Interestingly, we found that TH17 cells elicited by TGF-β and IL-6 signals migrated principally toward MIP-3α/CCL20 (Figure 8B). Of note, consistent with the suppression of CCR6 expression by 1,25(OH)2D3, 1,25(OH)2D3-treated TH17 cells migrated, to a much lesser degree, toward MIP-3α/CCL20 (Figure 8B). These results suggest that vitamin D3 inhibits the CCR6 expression on TH17 cells, which may block TH17 cells from entering the CNS.

Figure 8
1,25(OH)2D3 inhibits the expression of the CCR6 molecule in activated T cells.


In this study, we found that oral administration with 1,25(OH)2D3 significantly reduced the number of lymphocytes in the CNS of EAE-induced mice. The active form of vitamin D3 is a direct inhibitor for TH17 differentiation via the VDR signal but works independently of IL-2, IL-10, and STAT1 signals in vitro. In addition, we studied whether vitamin D3 negatively regulate the expression of IL-6R to inhibit TH17 differentiation but we did not see any significant differences in the IL-6R expression of CD4+ T cells after co-culture with IL-6, TGF-β and vitamin D3 (data not shown). Most importantly, 1,25(OH)2D3 negatively regulates the expression of CCR6 on the TH17 cells. Recently the CCR6-CCL20 axis was reported to play an essential role in controlling the entry of TH17 cells into the CNS, thus mediating the initiation of EAE [44]. Our data suggest the possibility that VDR activation modulates CCR6 expression and leads to a functional hypo-responsiveness to CCL20. Overall, our current results imply that oral administration of vitamin D3 could be an effective tool for the treatment of TH17-mediated autoimmune diseases.

Several recent studies reported the immunomodulatory effects of vitamin D3 on the differentiation and function of Treg cells, specifically the ability of topically applied vitamin D3 to increase the suppressive activity of Treg cells and the in vivo expansion of antigen-specific Treg cells following the topical application of calcipotriol, as a vitamin D3 analog [45], [46]. In addition, vitamin D3-treated DCs induce Treg cells via independence of an inhibitory receptor immunoglobulin-like transcript 3 (ILT3) molecule, which is required for induction of Treg [47]. These studies suggest that topical application of vitamin D3 might alter DC function in the periphery and affect the differentiation and functions of Treg cells. In contrast, our present data show that the expression of TGF-β mediated Foxp3 was inhibited by 1,25(OH)2D3 via the VDR signal on CD4+ T cells (Figure 4). In particular, in vitro treatment of 1,25(OH)2D3 resulted in decreased levels of IL-2 production by activated CD4+ T cells in concurrence with prior reports [48][50]. Thus, IL-2 might be crucial for inhibiting Treg differentiation by vitamin D3.

Although IL-2 blocks the inhibitory role of 1,25(OH)2D3 on Treg generation, 1,25(OH)2D3 and IL-2 synergistically constrain IL-17 production in CD4+ T cells (Figure 5). Thus, it seems likely that the mechanisms by which 1,25(OH)2D3 inhibits the generation of Treg and TH17 cells differ. The inhibitory effect of vitamin D3 seems to be similar to that of IL-27, which inhibits the lineage commitment of TH17 cells [33, 41–43 51] and induces IL-10 production, which, in turn, suppresses EAE initiation [34]. Since the ability of IL-27 to block the generation of TH17 cells is dependent on the transcription factor STAT1 [41][43], we next sought to determine whether STAT1 is involved in 1,25(OH)2D3-mediated inhibitory effects on the development of TH17 cells. However, unlike IL-27, 1,25(OH)2D3's ability to inhibit the development TH17 cells was independent on the STAT1.

A previous study demonstrated that Smad3, signal transducers of the TGF-β superfamily, mediated cross-talk between TGF-β and vitamin D3 signaling pathways [52]. The cooperative actions of the Smad3-VDR complex can be synergistic or antagonistic in a conditional manner [53]. In addition, another study suggested that the enhancement of TGF-β-driven Smad3 signaling by retinoic acid increases the number of Foxp3-expressing T cells and inhibits the development of TH17 cells [54]. These several lines of study lead us to speculate that Smad3 mediates vitamin D3's ability to inhibit the development of TH17 cells. However, as of yet we have not been able to verify this hypothesis.

Another study reported that the combination of vitamin D3 and dexamethasone increased the frequency at which IL-10-producing regulatory T cells are generated [55]. Further, vitamin D3 failed to inhibit EAE in IL-10−/− or IL-10R−/− B6 mice [32]. However, in our in vitro study, vitamin D3 alone failed to induce IL-10 production in activated T cells (Figure 6A and B). Thus, it requires additional factors to protect against EAE through the IL-10 effect. Vitamin D3 helped TGF-β mediate IL-10 production and strongly enhanced the generation of IL-27-mediated IL-10-producing CD4+ T cells in an in vitro system (Figure 6E). A recent study clearly showed that IL-27 plays a crucial role in the development of IL-10-producing anti-inflammatory T cells [40]. Others reported that IL-27 and IL-27R are up-regulated in APCs from the CNS and lymph nodes in EAE-induced mice [39]. When considered together, the facts that IL-27 is a good inducer of IL-10-producing T cells and that 1,25(OH)2D3 possesses synergistic effects under TH17-polarizing conditions suggest that vitamin D3 requires the presence of TGF-β and IL-6 to increase the number of IL-27-mediated IL-10-producing T cells. Thus, it is possible that vitamin D3 cooperates with IL-27 to protect against EAE through IL-10.

A recent study found that CCR6 plays an essential role in the initiation of EAE and that CCL20, a CCR6 ligand, is constitutively expressed in choroid plexus epithelial cells in mice and humans [44]. Further, TH17 cells predominantly express CCR6 [56]. In accordance, it has been suggested that the recruitment of TH17 cells via the CCR6-CCL20 axis is necessary for development of TH17 cell-mediated autoimmune disease. As depicted in Figure 1B, CD4+ T cells were highly infiltrated in EAE-induced mice whereas 1,25(OH)2D3-treated mice had extremely low numbers of CD4+ T cells in their CNS. However, although CCR6 are important for recruitment of TH17 cells into the mouse CNS, this has not yet been shown in human MS. Rather IL-17 and IL-22 receptors on blood-brain barrier endothelial cells play a crucial role on ICAM-1-mediated migration of TH17 in MS [8], [11]. Further study is required to elucidate differences between mouse and human receptors.

We raised two hypotheses to explain the absence of lymphocytes in the CNS after vitamin D3 treatment. First, we postulated that vitamin D3 causes lymphocyte death; however, vitamin D3 did not induce apoptosis and/or cell death of activated T cells under TH17-polarizing conditions (data not shown). Our second hypothesis was that regulation of TH17 cell recruitment occurs via chemokine and chemokine receptors. As expected, we found that 1,25(OH)2D3 inhibited the expression of CCR6 on T cells that had been activated by both TGF-β and IL-6 (Figure 8). Since one recent study also showed that vitamin D3 induces the expression of CCR10 on activated CD4+ T cells in the presence of IL-12 [57], we investigated the possibility that vitamin D3 also plays a role in the ability of TH17 cells to express CCR10 instead of CCR6. Those investigations showed that 1,25(OH)2D3 did not induce CCR10 expression on the TH17 cells in the presence of TGF-β and IL-6 (data not shown). Overall, we found that vitamin D3 down-regulates CCR6 but not CCR10 expression in the TH17-conditioned circumstance.

In summary, our study results suggest that vitamin D3 can directly regulate T cell development and migratory function. The VDR signal on the CD4+ T cells inhibits the expression of IL-17, IL-2, Foxp3, and CCR6 but enhances the expression of IL-10. These characteristic features of vitamin D3 could be applied to preventive and therapeutic strategies for TH17-mediated autoimmune diseases.

Materials and Methods


Female BALB/c and C57BL/6 mice (Charles River Laboratories, Seoul, Korea) were used at ages 8–12 wks. Rag2−/− DO11.10 mice (BALB/c background), MOG-TCR (2D2) transgenic mice (B6 background), IL-10−/− mice (B6 background), and STAT1−/− (B6 background) were purchased from Taconic (Germantown, NY) and Jackson Laboratory (Bar Harbor, ME). VDR−/− mice were kindly provided by Prof. S. Kato (University of Tokyo, Tokyo, Japan). All mice were maintained under pathogen-free conditions in the experimental facility at the International Vaccine Institute (Seoul, Korea) where they received sterilized food and water ad libitum and all experiments described in this article were approved by Institutional Animal Care and Use Committees (Approval No: PN 0901).

Vitamin D3 treatment and induction of EAE

One mg/ml stock of 1,25(OH)2D3 (Sigma-Aldrich, St. Louis, MO) in DMSO was added to water (50 ng/day for females; 100 ng/day for males). Alternatively, 200 ng of 1,25(OH)2D3 in oil or oil only as a placebo was injected i.p. [32]. To induce EAE, myelin oligodendrocyte glycoprotein peptide (MOG33–55, MEVGWYRSPFSRVVHLY-RNGK) was resuspended in sterile PBS to a concentration of 4 mg/ml and then emulsified with an equivalent volume of complete Freund's adjuvant (CFA) supplemented with 5 mg/ml Myocobacterium tuberculosis H37Ra (BD Diagnostic Systems, Sparks, MD). EAE was induced in 9- to 10-wk old female C57BL/6 mice by s.c. injection of 100 µl of MOG35–55/CFA homogenate delivering 200 µg of MOG35–55 peptide. On days 1 and 3 after immunization, the mice were injected i.p. with 200 ng of pertussis toxin (Sigma-Aldrich) diluted in PBS. The mice were then scored daily for clinical signs of EAE using the following scale for a “disease score”: 0 = no clinical disease, 1 = loss of tail tone, 2 = unsteady gait, 3 = hind limb paralysis, 4 = forelimb paralysis, 5 = death.

In vitro TH generation

All experiments were performed with highly purified CD4+CD25 naïve T cells (>95% purity). To purify naïve T cells, erythrocyte-depleted splenocytes were first depleted of CD25+ cells via magnetic selection using anti-CD25 microbeads (Miltenyi Biotec, Auburn, CA). In the remaining population, CD4+ cells were positively selected using anti-CD4 microbeads (Miltenyi Biotec). Cells were cultured in complete RPMI 1640 supplemented with 10% FBS and 50 U/ml of penicillin and streptomycin. For antigen-specific stimulation, purified CD4+ T cells from MOG TCR-Tg or Rag2−/− DO11.10 mice were incubated with MOG35–55 (25 µg/ml) or OVA323–339 (0.2 µM) peptide presented by CD3-depleted splenocytes under Treg-polarizing conditions (1 ng/ml rhTGF-β1, 10 µg/ml anti-IFN-γ, and 10 µg/ml anti-IL-4); under TH17-polarizing conditions (1 ng/ml rhTGF-β1, 20 ng/ml rmIL-6, 10 µg/ml anti-IFN-γ, and 10 µg/ml anti-IL-4); or under TH1-polarizing conditions (4 ng/ml rmIL-12 and 10 µg/ml anti-IL-4). Death cells were confirmed by propidium iodide (PI; BD Pharmingen, San Diego, CA) staining and were excluded before analysis.

Flow-cytometric analyses

CD4+ T cells were collected and stimulated with PMA (50 ng/ml; Sigma-Aldrich) and ionomycin (750 ng/ml; Calbiochem, La Jolla, CA) for 5 hr in the presence of Golgi Plug (BD Pharmingen). Anti-mouse CD3e-PerCP (145-2C11; BioLegend, San Diego, CA), anti-mouse CD4-FITC (RM4-5; BD Pharmingen), anti-mouse DO-11.10 Clonotypic TCR (KJ1-26; BD Pharmingen), anti-mouse TCR Vα3.2-FITC (RR3-16; BD Pharmingen), anti-mouse TCR Vβ 11 PE (RR3-15; BD Pharmingen), anti-mouse IL-17A-APC (eBio17B7; eBioscience, San Diego, CA), anti-mouse IFN-γ-APC (XMG1.2; BD Pharmingen), anti-mouse Foxp3-APC (FJK-16s; eBioscience), and anti-mouse IL-10-PE Abs (JES5-16E3; BD Pharmingen) were used according to manufacturers' instructions. Data were obtained using a FACSCalibur (BD Immunocytometry Systems, San Jose, CA) with CellQuest software and the profiles were analyzed using Flowjo flow cytometry software (TreeStar Inc., Ashland, OR).

Real-time PCR and RT-PCR

To assess the expression of IL-17 and Foxp3, mRNA was extracted using TRIzol (Invitrogen, Camarillo, CA) according to the manufacturer's instructions and then reverse transcribed into cDNA. The primer sequences for amplification of each transcript are as follows: IL-17, 5′-GGTCAACCTCAAAGTCTTTAACTC-3′ and 5′-TTAAAAAT GCAAGTAA GTTTGCTG-3′; Foxp3, 5′-CAGCTGCCTACAGTGCCCCTAG-3′ and 5′-CATTTGC CAGCAGTGGGTAG-3′; β-actin, 5′- ATCTGGCACCACACCTTCTACAATGAGCT GCG-3′ and 5′-CGTCATACTCCTGCTTGCTGATCCACAT CTGC-3′.

Chemotaxis assay

To evaluate the migration of TH17 cells, 5-µm Transwell inserts (Corning, Cambridge, MA) containing 1×105 in vitro-generated TH17 cells were placed in the 24-well plate so as to make contact with 600 µl of the medium alone (basal) or with 100 nM MIP-3α/CCL20 (R&D Systems, Minneapolis, MN). Two hours later, the inserts were removed and the population that migrated to the well bottoms was counted.


Data are expressed as the mean ± SD. Statistical comparisons between experimental groups were performed using the Student t-test.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by the Mid-Career Researcher Program through a NRF grant funded by the MEST (No. 2007-04213) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of Th17 cells. Nature. 2008;453:1051–1057. [PubMed]
2. Dong C. Th17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008;8:337–348. [PubMed]
3. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821–852. [PubMed]
4. Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43:402–407. [PMC free article] [PubMed]
5. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938–952. [PubMed]
6. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:566–573. [PubMed]
7. Steinman L. A brief history of Th17, the first major revision in the Th1/Th2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13:139–145. [PubMed]
8. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, et al. Human Th17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173–1175. [PubMed]
9. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disese in multiple sclerosis. Am J Pathol. 2008;172:146–155. [PubMed]
10. Brucklacher-Waldert V, Sturner K, Kolster M, Wolthausen J, Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009;132:3329–3341. [PubMed]
11. Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, et al. Preferential recruitment of Interferon-γ-expressing Th17 cells in multiple sclerosis. Ann Neruol. 2009;66:390–402. [PubMed]
12. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008;7:268–277. [PubMed]
13. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med. 1997;216:21–27. [PubMed]
14. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009;132:1146–1160. [PubMed]
15. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. Jama. 2006;296:2832–2838. [PubMed]
16. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62:60–65. [PubMed]
17. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–281. [PubMed]
18. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys. 2000;374:334–338. [PubMed]
19. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983;221:1181–1183. [PubMed]
20. Brennan A, Katz DR, Nunn JD, Barker S, Hewison M, et al. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology. 1987;61:457–461. [PubMed]
21. Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol. 1995;15:5789–5799. [PMC free article] [PubMed]
22. Cippitelli M, Santoni A. Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol. 1998;28:3017–3030. [PubMed]
23. Meehan MA, Kerman RH, Lemire JM. 1,25-Dihydroxyvitamin D3 enhances the generation of nonspecific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR. Cell Immunol. 1992;140:400–409. [PubMed]
24. Fritsche J, Mondal K, Ehrnsperger A, Andreesen R, Kreutz M. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood. 2003;102:3314–3316. [PubMed]
25. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164:2405–2411. [PubMed]
26. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, et al. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98:6800–6805. [PubMed]
27. D'Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappa B downregulation in transcriptional repression of the p40 gene. J Clin Invest. 1998;101:252–262. [PMC free article] [PubMed]
28. Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol. 2006;177:8504–8511. [PubMed]
29. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324:23–33. [PubMed]
30. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2008;8:685–98. [PMC free article] [PubMed]
31. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A. 1996;93:7861–7864. [PubMed]
32. Spach KM, Nashold FE, Dittel BN, Hayes CE. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:6030–6037. [PubMed]
33. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol. 2006;7:929–936. [PubMed]
34. Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol. 2007;8:1372–1379. [PubMed]
35. Staeva-Vieira TP, Freedman LP. 1,25-dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J Immunol. 2002;168:1181–1189. [PubMed]
36. Issa LL, Leong GM, Eisman JA. Molecular mechanism of vitamin D receptor action. Inflamm Res. 1998;47:451–475. [PubMed]
37. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201:723–735. [PMC free article] [PubMed]
38. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-beta to convert naive CD4+CD25 cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol. 2007;178:2018–2027. [PubMed]
39. Li J, Gran B, Zhang GX, Rostami A, Kamoun M. IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis. J Neurol Sci. 2005;232:3–9. [PubMed]
40. Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol. 2007;8:1380–1389. [PubMed]
41. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol. 2006;7:937–945. [PubMed]
42. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, et al. Th17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13:711–718. [PubMed]
43. Neufert C, Becker C, Wirtz S, Fantini MC, Weigmann B, et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol. 2007;37:1809–1816. [PubMed]
44. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, et al. C-C chemokine receptor 6-regulated entry of Th-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009;10:514–523. [PubMed]
45. Gorman S, Kuritzky LA, Judge MA, Dixon KM, McGlade JP, et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol. 2007;179:6273–6283. [PubMed]
46. Ghoreishi M, Bach P, Obst J, Komba M, Fleet JC, et al. Expansion of antigen-specific regulatory T cells with the topical vitamin D analog calcipotriol. J Immunol. 2009;182:6071–6078. [PubMed]
47. Penna G, Roncari A, Amuchastegui S, Daniel K C, Berti E, et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood. 2005;106:3490–3497. [PubMed]
48. Rigby WF, Stacy T, Fanger MW. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest. 1984;74:1451–1455. [PMC free article] [PubMed]
49. Lemire JM, Adams JS, Kermani-Arab V, Bakke AC, Sakai R, et al. 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol. 1985;134:3032–3035. [PubMed]
50. Bhalla AK, Amento EP, Krane SM. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol. 1986;98:311–322. [PubMed]
51. Diveu C, McGeachy MJ, Boniface K, Stumhofer JS, Sathe M, et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol. 2009;182:5748–5756. [PubMed]
52. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signaling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:465–471. [PubMed]
53. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science. 1999;283:1317–1321. [PubMed]
54. Xiao S, Jin H, Korn T, Liu SM, Oukka M, et al. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol. 2008;181:2277–2284. [PMC free article] [PubMed]
55. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, et al. A., In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 2002;195:603–616. [PMC free article] [PubMed]
56. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007;204:2803–2812. [PMC free article] [PubMed]
57. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, et al. DCs metabolize sunlight-induced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat Immunol. 2007;8:285–293. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science